Boston, MA, May 18 2020 – Today ViiV Healthcare announced the interim analysis of the HIV Prevention Trials Network (HPTN) 083 study evaluating the safety and efficacy of investigational, long-acting, injectable cabotegravir for HIV prevention. In the study, cabotegravir was …
Dr. Kenneth Mayer, Medical Research Director at The Fenway Institute, served as a Guest Editor on a new special issue of Journal of the International AIDS Society (JIAS). The supplemental issue, titled Understanding and addressing the HIV and STI syndemics…
Fenway Institute faculty members will be presenting at this year’s International AIDS Society (IAS) Conference in Mexico City July 21-24. The IAS Conference is the largest open scientific conference on HIV science in the world.
Kenneth Mayer, MD, Medical Research …
BOSTON, August 13, 2018—A new HIV prevention study published today in JAMA Pediatrics found that Project Lifeskills—a culturally specific, empowerment-based, and group-delivered behavioral prevention intervention—significantly reduced sexual risk for HIV acquisition and transmission in sexually active young transgender women …
Currently, no vaccine exists that can cure HIV, the virus that causes AIDS. Today, 36.7 million people are living with HIV/AIDS. Despite progress with antiretroviral therapy and other research dedicated to stopping this disease, there still is a dire need …
The BNAB (Broadly Neutralizing Antibody) study, also known as HPTN 087/HVTN 127, explores the tolerability and the impact that an experimental antibody has on the human immune system. The antibody being explored in this study is the VCRCO7-523LS antibody. According …
The Fenway Institute is proud to announce the enrollment of the 75th and final participant in the AMP (HPTN 085) study.
AMP (Antibody Mediated Prevention) is an HIV prevention study that tests the efficacy of an experimental antibody at …
On November 15 and 16 2017, The Fenway Institute’s Coordinating Center for Technical Assistance (CCTA) organized the National Convening for the Selections of Interventions at HRSA headquarters in Rockville, Maryland. CCTA is part of a new HRSA HIV/AIDS Bureau initiative …
An important new study examines the safety and efficacy of VRC01, a broadly neutralizing anti-HIV antibody, when administered as a long-term HIV prevention method. While earlier VRC01 research has shown the antibody to be safe for human use in short-term …
The Fenway Institute and Brown University are working together on the next phase of the groundbreaking study, Project ReACH—and we are looking for volunteers to continue this important research. Funded by the National Institutes of Health, Project ReACH examines …
